Literature DB >> 6512397

Acid posterior laryngitis. Aetiology, histology, diagnosis and treatment.

V Kambic, Z Radsel.   

Abstract

The authors have treated 44 patients with posterior chronic acid laryngitis. Biopsy was performed in all patients. Characteristic changes typical of the hyper-regenerative or atrophic phase of reflux oesophagitis were identified in all specimens. Gastric hypersecretion was proven in all but two patients. The aetiologic factors of acid posterior laryngitis are gastro-oesophageal reflux, with friction of both vocal processes during phonation and vocal abuse. The preferred therapy is removal of circumscribed lesions with a suitable medical regimen.

Entities:  

Mesh:

Year:  1984        PMID: 6512397     DOI: 10.1017/s0022215100148340

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  6 in total

Review 1.  Pediatric otolaryngologic manifestations of gastroesophageal reflux disease.

Authors:  Mark A Gilger
Journal:  Curr Gastroenterol Rep       Date:  2003-06

2.  Cough threshold in reflux oesophagitis: influence of acid and of laryngeal and oesophageal damage.

Authors:  L Benini; M Ferrari; C Sembenini; M Olivieri; R Micciolo; V Zuccali; G M Bulighin; F Fiorino; A Ederle; V L Cascio; I Vantini
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

3.  Peptic (contact ulcer) granuloma of the larynx.

Authors:  T L Miko
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

Review 4.  Airway protective mechanisms: current concepts.

Authors:  R Shaker
Journal:  Dysphagia       Date:  1995       Impact factor: 3.438

5.  Effect of omeprazole on the course of associated esophagitis and laryngitis.

Authors:  D Jaspersen; R Weber; C H Hammar; W Draf
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

6.  [Laryngeal granuloma. Aetiology, clinical signs, diagnostic procedures, and treatment].

Authors:  C Storck; M Brockmann; E Zimmermann; D Nekahm-Heis; P G Zorowka
Journal:  HNO       Date:  2009-10       Impact factor: 1.284

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.